IL6 and autoimmune disease: Nonetheless, because IL-6 cytokines predominantly utilize STAT3 pathway and the pathogenic Th17 cells that mediate CNS autoimmune diseases require STAT3 (31, 32), there is significant interest in developing therapies that target STAT3 pathway.